Trials / Terminated
TerminatedNCT03253185
A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SC-007 | intravenous |
Timeline
- Start date
- 2017-09-13
- Primary completion
- 2018-03-20
- Completion
- 2018-04-02
- First posted
- 2017-08-17
- Last updated
- 2018-04-27
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03253185. Inclusion in this directory is not an endorsement.